All In Biotech

Drug Trial Radar · NCT05190068

HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

A Multicenter, Open-label, Phase I Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of HMPL-760 in Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Last checked: Nov 19, 2026Latest source record: Apr 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

89

Actual

Start

Jan 4, 2022

Primary completion

Jan 27, 2025

Study completion Jan 27, 2025

Sponsor

Lead sponsor
HutchmedIndustry
Sponsor type
Industry
First posted
Jan 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Multicenter, Open-label, Phase I Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of HMPL-760 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Conditions

  • B-Cell Non-Hodgkin's Lymphoma

Interventions

  • HMPL-760Drug

    HMPL-760 was administered continuously as a single agent orally every day in sequential 28-day cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLTsTime frame: Up to 28 days after first dose of study drug.
  2. Safety and TolerabilityTime frame: Baseline up to the end of study

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • Chongqing university cancer hospital

    Chongqing, China

  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, China

  • Beijing Chao-Yang Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Xiamen University

    Xiameng, Fujian, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • Guangxi Medical University cancer Hospital & Guangxi Cancer Institute

    Nanning, Guangxi, China

  • Affiliated Hospital of Chengde Medical University

    Chengde, Hebei, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Chenzhou First People's Hospital

    Chenzhou, Hunan, China

  • First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • Jiangxi Cancer Hospital

    Nanchang, Jiangxi, China

  • Jilin Cancer Hospital

    Changchun, Jilin, China

  • The Second Affiliated Hospital of Dalian Medical University

    Dalian, Liaoning, China

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China

  • Harbin Medical University Cancer Hospital

    Harbin, Longjiang Hei, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • Heping Hospital Affiliated to Changzhi Medical College

    Changzhi, Shanxi, China

  • Shanxi Bethune Hospital

    Taiyuan, Shanxi, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

  • Affiliated Hangzhou First People's Hospital ,Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.